TNFRSF13B Antibody

What is TNFRSF13B and why is it significant for immunological research?

TNFRSF13B encodes the transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI), a B cell-specific tumor necrosis factor (TNF) receptor superfamily member. This receptor is critical for B-cell homeostasis and function, making it a valuable target for immunological investigations. TACI binds two important ligands: a proliferation-inducing ligand (APRIL) and B-cell-activating factor (BAFF) . These interactions are essential for establishing central B-cell tolerance and regulating B-cell development.

The significance of TNFRSF13B in research extends to its role in antibody production disorders. Both biallelic and monoallelic TNFRSF13B mutations have been identified in patients with common variable immunodeficiency disorders (CVID) and IgA deficiency (IgAD) . Approximately 11% of CVID patients and 13% of IgAD patients carry at least one mutated TNFRSF13B allele, with the most frequent variants being C104R and A181E . These associations make TNFRSF13B antibodies essential tools for investigating the molecular mechanisms underlying these immune disorders.

During later stages of B-cell development, TACI supports class-switch recombination, plasma cell differentiation, and antibody secretion, processes that can be studied using TNFRSF13B antibodies . Research has demonstrated that TNFRSF13B haploinsufficiency or null alleles result in decreased TACI expression on memory B-cells and impaired antibody secretion, highlighting the receptor's functional importance .

Where is TNFRSF13B primarily expressed and how can researchers detect it?

TNFRSF13B/TACI is predominantly expressed on B cells, with particular concentration on memory B cell populations. Immunohistochemical analysis has demonstrated TACI expression in human spleen, specifically in lymphocytes within the marginal zone . This expression pattern provides important context for researchers designing experiments targeting TACI-expressing cells.

For detecting TNFRSF13B in tissue samples, immunohistochemistry using anti-TNFRSF13B antibodies provides reliable results. A validated protocol involves using antigen affinity-purified polyclonal antibodies against human TACI/TNFRSF13B at a concentration of approximately 10 μg/mL, applied to immersion-fixed paraffin-embedded tissue sections overnight at 4°C . Prior to antibody application, heat-induced epitope retrieval should be performed using an appropriate antigen retrieval reagent. The signal can be visualized using an HRP-DAB staining system, with hematoxylin counterstaining to provide tissue context.

Flow cytometry represents another critical method for detecting TNFRSF13B expression on specific B cell subsets in blood or isolated lymphocyte populations. This technique allows quantification of TACI expression levels and correlation with other cell surface markers to identify discrete B cell populations with varying TACI expression profiles.

How can TNFRSF13B antibodies be applied to study CVID and IgA deficiencies?

TNFRSF13B antibodies provide sophisticated tools for investigating the molecular and cellular mechanisms underlying CVID and IgA deficiencies through several methodological approaches:

For genotype-phenotype correlation studies, researchers can use TNFRSF13B antibodies to determine how different mutations affect TACI protein expression, localization, and function. Studies have shown that approximately 7% of CVID patients have monoallelic TNFRSF13B mutations, while 4% have biallelic mutations . Similarly, 13.4% of IgA deficiency patients carry at least one mutated TNFRSF13B allele .

Functional assessment experiments combining TNFRSF13B antibody staining with ligand binding assays can evaluate how mutations affect TACI's ability to interact with APRIL and BAFF. Research has demonstrated that patients with biallelic TNFRSF13B mutations consistently show impaired binding to APRIL, providing mechanistic insights into the functional consequences of these mutations .

For diagnostic applications, flow cytometric analysis using TNFRSF13B antibodies can help identify patients with TACI deficiency even before genetic testing. Characteristic patterns of diminished TACI expression on memory B cells can serve as a screening tool to identify candidates for TNFRSF13B sequencing.

What controls should be included when working with TNFRSF13B antibodies?

Robust experimental design requires appropriate controls to ensure valid interpretation of results when using TNFRSF13B antibodies:

Tissue controls should include spleen sections as positive controls, particularly focusing on marginal zone lymphocytes, which have demonstrated reliable TACI expression in validation studies . Tissues known not to express TACI should be included as negative controls to confirm staining specificity.

Genetic controls provide the most definitive validation system. When available, samples from individuals with known TNFRSF13B genotypes (wild-type, heterozygous, or homozygous for specific mutations) offer valuable reference points for antibody binding patterns. Studies have identified distinctive expression patterns in patients with biallelic versus monoallelic mutations that can serve as benchmarks .

For flow cytometry applications, matching isotype control antibodies are essential to distinguish specific staining from non-specific binding. Additionally, blocking controls involving pre-incubation of the TNFRSF13B antibody with recombinant TACI protein should abolish specific staining, confirming antibody specificity.

Implementation of these controls is particularly important when studying subtle differences in TACI expression between carriers of different TNFRSF13B variants, as these may have significant functional consequences despite modest changes in expression levels.

How do monoallelic versus biallelic TNFRSF13B mutations affect protein detection using antibodies?

Distinguishing between monoallelic and biallelic TNFRSF13B mutations presents an important challenge in research settings. Different mutation patterns create distinct detection profiles that researchers must recognize when interpreting antibody-based assays:

Quantitative flow cytometry can distinguish between these genetic states by precisely measuring TACI expression levels on B cells. Biallelic mutations typically result in more severely reduced TACI expression compared to monoallelic mutations. This quantitative approach requires calibrated flow cytometry using standardized beads to convert fluorescence intensity to absolute receptor numbers per cell.

For common mutations like C104R and A181E, developing epitope-specific antibodies that differentially recognize wild-type versus mutant TACI protein forms would allow direct assessment of mutant protein expression. This approach would be particularly valuable for studying how heterozygous mutations affect TACI function at the protein level.

What methodological approaches can detect functional consequences of TNFRSF13B mutations?

Several sophisticated methodological approaches employing TNFRSF13B antibodies can reveal the functional impacts of TNFRSF13B mutations:

Ligand binding assays using fluorescently labeled APRIL or BAFF alongside TNFRSF13B antibodies can assess receptor-ligand interactions. Studies have shown that patients with biallelic mutations had significantly impaired binding to APRIL, providing a functional readout of mutation severity .

Signaling pathway analysis following TACI engagement can be performed using phospho-specific antibodies against downstream signaling molecules. This approach reveals how mutations affect signal transduction after receptor activation. Research has demonstrated that intracellular TACI domains interact with several signaling molecules, including myeloid differentiation factor 88 (MyD88), as well as activated endosomal toll-like receptors (TLR) 7 and TLR9 .

Multi-parameter flow cytometry combining TNFRSF13B antibodies with functional readouts can correlate receptor expression with cellular responses. For example, researchers have observed that heterozygosity for the C104R mutation is associated with low numbers of IgD-CD27+ B cells (P = 0.019), benign lymphoproliferation (P < 0.001), and autoimmune complications (P = 0.001) . These associations can be further characterized using comprehensive immunophenotyping.

Co-localization studies using confocal microscopy with fluorescently labeled TNFRSF13B antibodies can determine whether mutations affect receptor clustering or subcellular localization, providing insights into potential mechanisms of dysfunction.

How can TNFRSF13B antibodies contribute to transplantation research?

Recent research has revealed an unexpected connection between TNFRSF13B genotypes and transplant rejection, offering novel applications for TNFRSF13B antibodies in transplantation studies:

Analysis of TNFRSF13B in human kidney transplant recipients revealed that 33% of those with antibody-mediated rejection (AMR) had TNFRSF13B missense mutations, compared to fewer than 6% of those with stable graft function . This striking association provides a compelling rationale for incorporating TNFRSF13B antibodies into transplantation research protocols.

Mechanistic studies suggest that TNFRSF13B variants influence transplant outcomes not by increasing alloantibody production, but by decreasing "natural" IgM and compromising complement regulation . This leads to complement deposition in allografted hearts and autogenous kidneys. These findings indicate that multi-parameter analyses combining TNFRSF13B antibodies with markers for natural antibodies and complement components would provide the most comprehensive insights.

For monitoring transplant rejection risk, flow cytometric panels incorporating TNFRSF13B antibodies with other markers of B cell activation could potentially identify patients at higher risk for antibody-mediated rejection. This approach could be particularly valuable in patients with known TNFRSF13B mutations, who appear to have a significantly elevated risk for developing AMR.

What role does TNFRSF13B play in natural antibody production and host defense?

TNFRSF13B antibodies have helped uncover unexpected relationships between TACI function, natural antibody production, and host defense against pathogens:

The high frequency of dominant negative TNFRSF13B alleles across multiple species suggests these variants may confer adaptive advantages in certain contexts . Research using animal models has demonstrated that mice engineered to express TNFRSF13B variants corresponding to human mutations exhibited striking resistance to certain enteric pathogens .

Mechanistic studies revealed that wild-type but not mutant mice had natural enteric IgA that bound to specific pathogens, suggesting TNFRSF13B plays a complex role in regulating natural antibody production . These findings can be further explored using TNFRSF13B antibodies to characterize B cell subsets responsible for natural antibody production in carriers of different TNFRSF13B genotypes.

The complex relationship between TNFRSF13B and natural antibodies extends to transplantation outcomes, where TNFRSF13B mutations appear to decrease natural IgM and compromise complement regulation . This dual impact on antibody production and complement activity reveals TNFRSF13B as a critical regulator of multiple immune pathways.

These findings suggest that TNFRSF13B polymorphisms may represent a "double-edged sword," providing protection against certain pathogens while potentially increasing susceptibility to antibody-mediated pathologies in other contexts .

How should researchers interpret conflicting results when using different TNFRSF13B antibodies?

When facing discrepancies between results obtained using different TNFRSF13B antibodies, researchers should consider several methodological factors:

Epitope differences represent a primary consideration, as different antibodies may target distinct regions within the TACI protein. If these epitopes are differentially affected by specific mutations, protein interactions, or conformational changes, seemingly conflicting results may actually provide complementary information about TACI biology. The most common TNFRSF13B variants (C104R and A181E) affect specific domains that may impact antibody binding depending on epitope location .

Validation status varies considerably between commercially available antibodies. Priority should be given to results obtained with extensively validated antibodies that have demonstrated specificity through multiple approaches, such as those validated in marginal zone lymphocytes of human spleen .

The high polymorphism of TNFRSF13B across species and the frequent dominant negative phenotypes observed highlight the complex biology of this receptor . This complexity may manifest as apparent contradictions when using different detection reagents, requiring careful correlation with functional data for proper interpretation.

What are the optimal approaches for studying TNFRSF13B in the context of B cell development?

Studying TNFRSF13B's role in B cell development requires specialized methodological approaches:

Developmental staging using multi-parameter flow cytometry combining TNFRSF13B antibodies with markers of B cell maturation (CD19, CD27, IgD, etc.) allows precise characterization of TACI expression throughout B cell development. Research has shown that TNFRSF13B haploinsufficiency or null alleles result in decreased TACI expression specifically on memory B cells .

In vitro differentiation assays where B cells are stimulated to undergo class switching and plasma cell differentiation can be monitored using TNFRSF13B antibodies to track changes in receptor expression during these processes. Studies have demonstrated that TACI supports class-switch recombination, plasma cell differentiation, and antibody secretion during later stages of B cell development .

For assessing tolerance mechanisms, TNFRSF13B antibodies can be used to study how TACI contributes to eliminating autoreactive B cells. Research has established that TACI is essential for the establishment of central B-cell tolerance, and subjects carrying C104R and A181E missense TNFRSF13B mutations have impaired ability to remove developing autoreactive B cells in bone marrow .

When studying B cell development in the context of TNFRSF13B mutations, it is important to note that heterozygosity for C104R has been associated with low numbers of IgD-CD27+ B cells (P = 0.019) , suggesting specific developmental pathways may be particularly sensitive to TACI dysfunction.